AGNC Investment Corp vs BioNTech SE - ADR — how do they compare? AGNC Investment Corp trades at $10.91 (market cap $12.91B), while BioNTech SE - ADR trades at $92.94 (market cap $23.31B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and AGNC Investment Corp pays a 13.22% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| AGNC | BNTX | |
|---|---|---|
Market Cap | $12.91B | $23.31B |
Sector | Financials | Health |
52-Week High | $12.17 | $119.34 |
52-Week Low | $9.46 | $83.89 |
Dividend Yield | 13.22% | — |
Enterprise Value | — | $6.60B |
Signals from Pluang's Aura AI — not financial advice
AGNC Investment trades at $10.925, up 1.53% today, with a bullish technical signal from moving averages. The mortgage REIT shows strong profitability with a 94.38% net income margin and 21.67% ROE, though it missed Q4 2025 EPS estimates. Recent analyst upgrades and consistent monthly dividends highlight income appeal, while the stock trades modestly above its $8.58 book value. Cash flow trends indicate active portfolio management with significant investing and financing activities.
Outlook: AGNC offers high yield income potential with a secure dividend history, but faces interest rate sensitivity and valuation constraints. Risks include mortgage spread volatility and leveraged portfolio exposure. Analyst consensus is mixed with a $11.30 price target suggesting limited upside from current levels.
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Trailing returns across standard periods
Latest headlines on both assets
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →